New Drug Developments in Metastatic Gastric Cancer

Overview

Journal Therap Adv Gastroenterol

Publisher Sage Publications

Specialty Gastroenterology

Date 2018 Nov 21

PMID 30455742

Citations 12

Authors

Aaron C Tan

David L Chan

Wasek Faisal

Nick Pavlakis

Affiliations

Soon will be listed here.

Abstract

Metastatic gastric cancer is associated with a poor prognosis and novel treatment options are desperately needed. The development of targeted therapies heralded a new era for the management of metastatic gastric cancer, however results from clinical trials of numerous targeted agents have been mixed. The advent of immune checkpoint inhibitors has yielded similar promise and results from early trials are encouraging. This review provides an overview of the systemic treatment options evaluated in metastatic gastric cancer, with a focus on recent evidence from clinical trials for targeted therapies and immune checkpoint inhibitors. The failure to identify appropriate predictive biomarkers has hampered the success of many targeted therapies in gastric cancer, and a deeper understanding of specific molecular subtypes and genomic alterations may allow for more precision in the application of novel therapies. Identifying appropriate biomarkers for patient selection is essential for future clinical trials, for the most effective use of novel agents and in combination approaches to account for growing complexity of treatment options.

Citing Articles

Overexpression of ELF1 combined with MMP9 is associated with prognosis and tumor microenvironment in gastric cancer.

Zhang X, Ren X, Zhang S, Wang Y Exp Ther Med. 2024; 28(6):441.

PMID: 39583246 PMC: 11582528. DOI: 10.3892/etm.2024.12730.

Chromosomal Instability in Gastric Cancer: Role in Tumor Development, Progression, and Therapy.

Nemtsova M, Kuznetsova E, Bure I Int J Mol Sci. 2023; 24(23).

PMID: 38069284 PMC: 10707305. DOI: 10.3390/ijms242316961.

Modulation of Spheroid Forming Capacity and TRAIL Sensitivity by KLF4 and Nanog in Gastric Cancer Cells.

To H, Le Q, Bui H, Park J, Kang D Curr Issues Mol Biol. 2023; 45(1):233-248.

PMID: 36661504 PMC: 9857986. DOI: 10.3390/cimb45010018.

NOL6 Regulates the Proliferation and Apoptosis of Gastric Cancer Cells Regulating TP53I3, CDK4 and MCM7 Expression.

He L, Qian X, Ge P, Fan D, Ma X, Wu Q Front Oncol. 2022; 12:708081.

PMID: 35494047 PMC: 9039204. DOI: 10.3389/fonc.2022.708081.

Collagen family genes and related genes might be associated with prognosis of patients with gastric cancer: an integrated bioinformatics analysis and experimental validation.

Weng K, Huang Y, Deng H, Wang R, Luo S, Wu H Transl Cancer Res. 2022; 9(10):6246-6262.

PMID: 35117235 PMC: 8797647. DOI: 10.21037/tcr-20-1726.

References

Ciardiello F, Tortora G . EGFR antagonists in cancer treatment. N Engl J Med. 2008; 358(11):1160-74. DOI: 10.1056/NEJMra0707704. View

Troiani T, Napolitano S, Della Corte C, Martini G, Martinelli E, Morgillo F . Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence. ESMO Open. 2016; 1(5):e000088. PMC: 5070253. DOI: 10.1136/esmoopen-2016-000088. View

Appleman L . MET signaling pathway: a rational target for cancer therapy. J Clin Oncol. 2011; 29(36):4837-8. DOI: 10.1200/JCO.2011.37.7929. View

Al-Batran S, Hartmann J, Probst S, Schmalenberg H, Hollerbach S, Hofheinz R . Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol. 2008; 26(9):1435-42. DOI: 10.1200/JCO.2007.13.9378. View

Satoh T, Xu R, Chung H, Sun G, Doi T, Xu J . Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study. J Clin Oncol. 2014; 32(19):2039-49. DOI: 10.1200/JCO.2013.53.6136. View

Lordick F, Kang Y, Chung H, Salman P, Oh S, Bodoky G . Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. Lancet Oncol. 2013; 14(6):490-9. DOI: 10.1016/S1470-2045(13)70102-5. View

Bang Y, Van Cutsem E, Feyereislova A, Chung H, Shen L, Sawaki A . Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010; 376(9742):687-97. DOI: 10.1016/S0140-6736(10)61121-X. View

Hecht J, Bang Y, Qin S, Chung H, Xu J, Park J . Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial. J Clin Oncol. 2015; 34(5):443-51. DOI: 10.1200/JCO.2015.62.6598. View

Bilgin B, Sendur M, Akinci M, Dede D, Yalcin B . Targeting the PD-1 pathway: a new hope for gastrointestinal cancers. Curr Med Res Opin. 2017; 33(4):749-759. DOI: 10.1080/03007995.2017.1279132. View

10.

Koizumi W, Yamaguchi K, Hosaka H, Takinishi Y, Nakayama N, Hara T . Randomised phase II study of S-1/cisplatin plus TSU-68 vs S-1/cisplatin in patients with advanced gastric cancer. Br J Cancer. 2013; 109(8):2079-86. PMC: 3798959. DOI: 10.1038/bjc.2013.555. View

11.

Graziano F, Galluccio N, Lorenzini P, Ruzzo A, Canestrari E, DEmidio S . Genetic activation of the MET pathway and prognosis of patients with high-risk, radically resected gastric cancer. J Clin Oncol. 2011; 29(36):4789-95. DOI: 10.1200/JCO.2011.36.7706. View

12.

Qing Y, Li Q, Ren T, Xia W, Peng Y, Liu G . Upregulation of PD-L1 and APE1 is associated with tumorigenesis and poor prognosis of gastric cancer. Drug Des Devel Ther. 2015; 9:901-9. PMC: 4338255. DOI: 10.2147/DDDT.S75152. View

13.

Okines A, de Castro D, Cunningham D, Chau I, Langley R, Thompson L . Biomarker analysis in oesophagogastric cancer: Results from the REAL3 and TransMAGIC trials. Eur J Cancer. 2013; 49(9):2116-25. DOI: 10.1016/j.ejca.2013.02.007. View

14.

Muro K, Chung H, Shankaran V, Geva R, Catenacci D, Gupta S . Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. Lancet Oncol. 2016; 17(6):717-726. DOI: 10.1016/S1470-2045(16)00175-3. View

15.

Rizvi N, Hellmann M, Snyder A, Kvistborg P, Makarov V, Havel J . Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015; 348(6230):124-8. PMC: 4993154. DOI: 10.1126/science.aaa1348. View

16.

Glimelius B, Ekstrom K, Hoffman K, Graf W, Sjoden P, Haglund U . Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol. 1997; 8(2):163-8. DOI: 10.1023/a:1008243606668. View

17.

Cristescu R, Lee J, Nebozhyn M, Kim K, Ting J, Wong S . Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nat Med. 2015; 21(5):449-56. DOI: 10.1038/nm.3850. View

18.

Li J, Qin S, Xu J, Xiong J, Wu C, Bai Y . Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction. J Clin Oncol. 2016; 34(13):1448-54. DOI: 10.1200/JCO.2015.63.5995. View

19.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

20.

Kim M, Lee H, Lee H, Jeon Y, Yang H, Kim W . EGFR in gastric carcinomas: prognostic significance of protein overexpression and high gene copy number. Histopathology. 2008; 52(6):738-46. DOI: 10.1111/j.1365-2559.2008.03021.x. View